University of Vermont
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Vermont sits in the top decile of US sponsors by registered trial count (#183 of 15,742 sponsors by registered trial count).
University of Vermont: 162 sponsored US clinical trials, 15 recruiting.
University of Vermont sponsors 162 registered US clinical trials on ClinicalTrials.gov, 15 of them currently recruiting, and 132 completed. 5 of these trials are in Phase 3-4 (later-stage) and 49 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid-Related Disorders, with 4 trials.
Top-decile sponsor footprint
University of Vermont ranks in the top decile of sponsors by registered trial count (#183 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
132 of 141 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
162 total, page 1 of 4
Prolonged Exposure Therapy to Treat Posttraumatic Stress Disorder in Pregnant Patients
NCT06670079
Fezolinetant for Treating Hot Flashes in Men With Prostate Cancer
NCT06972875
Food Insecurity and Eating Behavior Among Adults Receiving Buprenorphine or Methadone Maintenance Treatment: Pilot Study 2
NCT07251283
DOAC - Dosing Options in AntiCoagulation Prophylaxis
NCT07005024
Contingency Management to Improve Medication for Opioid Use Disorder Continuation After the Emergency Department
NCT07129902
Comparing the Effectiveness of the 'Think in Nerve Length and Layers' (TINLL) Approach to Traditional Treatment for Patients With Lateral Elbow Pain.
NCT07385677
Defining Inflammatory Markers of Cardiovascular Disease in Patients With Myelodysplastic Syndromes
NCT06692894
Nicotine Regulation for Dual Users of E-cigarettes and Cigarettes
NCT06614504
Novel Telemedicine-Delivered Prolonged Exposure Therapy for Treating PTSD in Individuals With OUD
NCT06288711
Fatty Acid Modulation of Brain Function in Older Adults
NCT06192407
LEMURS SSI: Evaluation of Behavioral Incentives
NCT06340841
PRESERVE & CONNECT: Impact Study of the BPC
NCT06160050
Accelerated Pulmonary Rehabilitation in the Preoperative Period
NCT06432972
Remote Monitoring and Management of Chemotherapy Induced Peripheral Neuropathy
NCT04763356
Neuromuscular Electrical Stimulation in COPD/Community Acquired Pneumonia
NCT05452226
Phase 1 Trial of Endobronchial Ultrasound-Guided Transbronchial Needle Injection of Cisplatin for Stage IV Lung Cancer
NCT04311762
Communication During Hospitalization About Resuscitation Trial
NCT02984124
Zinc Therapy in Critical Illness
NCT01162109
PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)
NCT07477418
RE-FIT (Remote Exercise for Physical Function in WTC Responders With Prostate Cancer)
NCT07440641
A Multi-Site Hybrid Type I Effectiveness-Implementation Randomized Trial of an Emergency Care Action Plan for Infants With Medical Complexity
NCT06993129
Pilot of Exercise and Asthma Control
NCT06651385
Developing a Digital Intervention to Prevent Risky Health Behaviors
NCT06538922
Financial Incentives to Promote Stimulant Abstinence in a Community-Based Syringe Exchange Program
NCT05787847
The Lived Experiences Measured Using Rings Pilot Study
NCT05841979
Choline and Brain Functioning in Postmenopausal Women
NCT07264257
Pulmonary and Cardiac Effects of E-Cigarette Use in Pulmonary Patients Who Smoke Cigarettes
NCT05610514
Evaluating a Telemedicine Neurological Consult Program for Drug-Induced Movement Disorders Using the RE-AIM Framework
NCT06060444
Novel Intervention to Improve Food Insecurity Among Individuals With Opioid Use Disorder
NCT06374303
Technology-delivered Physical Activity Program for Adolescents With Type 1 Diabetes
NCT05319600
Remote Incentives for Smoking Cessation Among AN Pregnant Women
NCT05019170
Neck Cooling as a Non-Invasive Method to Lower Brain Temperature in Healthy Adults
NCT04973085
Quit Smoking Study for People Who Use E-Cigarettes
NCT04946825
Cannabis Tolerance Break Resource Study: T-Break Guide
NCT05382273
Survivors Taking Action With Remote Exercise Training
NCT04806139
Intratumoral Cisplatin for Resectable NSCLC
NCT04809103
Do Flavors Increase the Addiction Potential of Nicotine?
NCT04696380
Impact of Nicotine Messaging on Nicotine Beliefs and Tobacco Use Behavior
NCT04805515
Understanding Immunology and Patient Outcomes of COVID-19 in Hospitalized Patients
NCT04892797
E-cigarette Nicotine Study
NCT04709471
Low Nicotine Content Cigarettes in Vulnerable Populations: Opioid Use Disorder
NCT04092101
Low Nicotine Content Cigarettes in Vulnerable Populations: Women of Reproductive Age
NCT04092387
PACE Vape Messaging Study
NCT04450537
Improving Smoking Cessation in Socioeconomically-Disadvantaged Young Adults
NCT04379388
COVID Cohort Study
NCT04393155
Cholinergic Health After Menopause (CHAMP)
NCT04129060
Determination of the Diagnostic Detection Rate of Axumin (Fluciclovine) Digital PET/CT, Post-prostatectomy
NCT04234399
MitoQ for the Treatment of Metabolic Dysfunction in Asthma
NCT04026711
Prolonged Exposure Therapy for PTSD and Opioid Use Disorder
NCT04104022
Start Treatment and Recovery for Opioid Use Disorder
NCT04505540
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 23 |
| Phase 2 | 26 |
| Phase 3 | 2 |
| Phase 4 | 3 |
Therapeutic Areas
What is open in the University of Vermont pipeline
15 recruiting of 162 indexed (9% open); 132 completed (81%).
Phase mix: 5 late (III/IV) vs 49 early (I/II) (early-phase heavy).
Top condition: Opioid-Related Disorders (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Vermont: open-pipeline peers nationwide
Peers matched on 162 registered trials and 9% open enrollment, not the therapeutic-area sidebar.
University of Vermont sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 162 trials (± recruiting share)
- Alexion Pharmaceuticals · 162 trials · 10% recruiting
- Temple University · 163 trials · 13% recruiting
- Tufts University · 163 trials · 6% recruiting
- Wayne State University · 163 trials · 13% recruiting
Sponsors near 9% open enrollment (± trial volume)
- Shionogi · 9% recruiting · 54 trials
- University of Kentucky · 9% recruiting · 54 trials
- Eli Lilly and Company · 9% recruiting · 1,341 trials
- Lahey Clinic · 9% recruiting · 43 trials
Related
What to do with this University of Vermont page
162 registered trials is a research-attention snapshot, not an endorsement of University of Vermont or any single study.
- 15 of University of Vermont's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Opioid-Related Disorders is the condition University of Vermont studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid-Related Disorders trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of Vermont pipeline card: 162 registered trials from official public datasets.Report a data error.